|  | Meta-analyses | 50%1 | 75% | 90% | 99% | Max |
---|---|---|---|---|---|---|---|
All | Total | 22453 | 3 | 6 | 10 | 28 | 294 |
Data type | Dichotomous | 14886 | 3 | 6 | 10 | 28 | 294 |
 | Continuous | 6672 | 3 | 5 | 8 | 24 | 98 |
 | Mixed | 895 | 4 | 7 | 12 | 46 | 133 |
Medical specialty | Cancer | 905 | 5 | 8 | 14 | 43 | 69 |
 | Cardiovascular | 1693 | 4 | 7 | 13 | 38 | 58 |
 | Central nervous system/musculoskeletal | 1965 | 3 | 5 | 8 | 21 | 49 |
 | Digestive/endocr., nutritional and metabolic | 2704 | 4 | 6 | 11 | 31 | 138 |
 | Gynaecology, pregnancy and birth | 4656 | 3 | 5 | 8 | 20 | 76 |
 | Infectious diseases | 965 | 3 | 5 | 9 | 27 | 63 |
 | Mental health and behavioural conditions | 2918 | 3 | 5 | 10 | 30 | 174 |
 | Pathological conditions, symptoms and signs | 701 | 3 | 6 | 10 | 31 | 294 |
 | Respiratory diseases | 3021 | 3 | 5 | 8 | 20 | 39 |
 | Urogenital | 1289 | 3 | 5 | 9 | 21 | 31 |
 | Other | 1636 | 3 | 6 | 10 | 34 | 133 |
Interventions | Pharm. vs. Control/Placebo | 8348 | 3 | 6 | 10 | 30 | 294 |
 | Pharm. vs. Pharm. | 5571 | 3 | 6 | 10 | 28 | 174 |
 | Pharm. vs. Non-Pharm. | 424 | 3 | 5 | 11 | 25 | 36 |
 | Non-Pharm. vs. Control/Placebo | 4449 | 3 | 5 | 9 | 25 | 61 |
 | Non-Pharm. vs. Non-Pharm. | 3661 | 3 | 5 | 9 | 28 | 58 |
Outcomes | Signs/symptoms reflecting continuation/end of condition | 3639 | 3 | 5 | 9 | 29 | 110 |
 | Adverse events | 2368 | 3 | 6 | 10 | 26 | 270 |
 | Infection/onset of new acute/chronic disease | 2215 | 3 | 6 | 10 | 24 | 294 |
 | Biological markers | 2071 | 3 | 6 | 10 | 28 | 138 |
 | General physical health | 1921 | 3 | 5 | 9 | 27 | 58 |
 | Obstetric outcomes | 1477 | 3 | 6 | 11 | 24 | 76 |
 | All-cause mortality | 1278 | 4 | 8 | 13 | 36 | 75 |
 | Resource use/hospital stay/process | 1187 | 3 | 5 | 9 | 27 | 99 |
 | Cause-specific mortality/major morbidity event/composite (mortality or morbidity) | 920 | 4 | 6 | 11 | 34 | 133 |
 | Other outcomes (semi-objective)2 | 2044 | 3 | 6 | 11 | 30 | 174 |
 | Other outcomes (subjective)3 | 3239 | 3 | 5 | 9 | 23 | 69 |